-
Wu Yilong/Zhong Wenzhao's team found that immuno+ chemotherapy neoadjuvant treatment regimens may
Time of Update: 2022-12-30
In order to clarify this problem, the team of Professor Wu Yilong and Professor Zhong Wenzhao of Guangdong Provincial People's Hospital conducted a multicenter retrospective study to evaluate the clinical results and safety of neoadjuvant immunotherapy combined with chemotherapy in driver gene-positive resectable NSCLC, and explored the potential mechanisms leading to differences in efficacy of neoadjuvant immunotherapy through dynamic multiomics sequencing, the results of which have been published in NPJ Precision Oncology [3].
-
abnormally, Wu Zhong, Changxin Chemical and other enterprises are named
Time of Update: 2022-05-29
Due to the inadequate pollution control measures and the abnormal operation of environmental protection facilities, the Second Ecological Environmental Protection Supervision Team of the Party Committee of Ningxia Hui Autonomous Region recently conducted investigations on Wuzhong Changxin Chemical Co.
-
China Nutrition Society helps Wu Zhong City build "China stuffed selenium capital"
Time of Update: 2020-10-22
April 13-14, 2017, the China Association of Science and Technology Innovation Drive Project Summary Exchange was held in Ningbo City, Zhejiang Province.
-
Wu Zhong pharmaceutical's class I anticancer drug (Su Qiujia) clinical trial failed for a long time, and shareholders began to fire at the management
Time of Update: 2015-04-25
On April 17, Jiangsu Wuzhong (600200) annual general meeting of shareholders, the company is in clinical trials of a class of original anti-cancer drug research project (Su Qiujia) due to the delay ca